Yomna Ali Abdelghafar
YOU?
Author Swipe
View article: Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta‐analysis
Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta‐analysis Open
Background Etrolizumab is a promising drug for treating moderate to severe ulcerative colitis. Aim The aim of this study was to assess the efficacy and safety of etrolizumab for induction and maintenance of remission in moderate to severe …
View article: Fascia iliaca compartment block for postoperative pain after total hip arthroplasty: a systematic review and meta-analysis of randomized controlled trials
Fascia iliaca compartment block for postoperative pain after total hip arthroplasty: a systematic review and meta-analysis of randomized controlled trials Open
Background Fascia iliaca compartment block (FICB) is one of the regional nerve blocks used to reduce pain after total hip arthroplasty (THA). We aim to assess the efficacy of FICB in reducing post-operative pain and opioid consumption. Met…
View article: Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials
Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials Open
Introduction: Irritable bowel syndrome (IBS) is the most common functional gastrointestinal tract disorder. Bacillus coagulans (BC) is a potent spore-forming probiotic that has been proposed as a potent supplement that can improve gastroin…
View article: A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH Open
Key Clinical Message Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatre…
View article: Bacillus Coagulans as potent intervention for irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials
Bacillus Coagulans as potent intervention for irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials Open
Introduction: Irritable bowel syndrome (IBS) is the most common functional GIT disorder. Bacillus coagulans (BC) is a potent spore-forming probiotic that has been proposed as a potent supplement that can improve GIT dysbiosis and relieve I…
View article: Prevalence and patterns of premenstrual disorders and possible association with sexual harassment: a cross-sectional study of young Arab women
Prevalence and patterns of premenstrual disorders and possible association with sexual harassment: a cross-sectional study of young Arab women Open
View article: Therapeutic effect of Internal iliac artery ligation and uterine artery ligation techniques for bleeding control in placenta accreta spectrum patients: A meta-analysis of 795 patients
Therapeutic effect of Internal iliac artery ligation and uterine artery ligation techniques for bleeding control in placenta accreta spectrum patients: A meta-analysis of 795 patients Open
Placenta accreta spectrum (PAS) can cause complications like hysterectomy or death due to massive pelvic bleeding. We aim to evaluate the efficacy of two different arterial ligation techniques in controlling postpartum haemorrhage and mini…
View article: Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials
Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials Open
Background and Aims Fecal microbiota transfer (FMT) is a potential treatment for irritable bowel syndrome (IBS). Several randomized trials have tested FMT effects using different routes of administration, doses, and sample sizes. We aim to…